Showing 5331-5340 of 7146 results for "".
- Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for Psoriasishttps://practicaldermatology.com/news/dermavant-completes-patient-enrollment-for-two-phase-3-clinical-trials-of-tapinarof-for-psoriasis/2460339/Dermavant Sciences completed patient enrollment in PSOARING 1 and PSOARING 2 clinical trials of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA), in adult patients diagnosed with plaque psoriasis. Dermavant expects t
- Antimalarials for COVID-19: Will Demand Outweigh Supply?https://practicaldermatology.com/news/antimalarials-for-covid-19-will-demand-outweigh-supply/2460337/Chloroquine and hydroxychloroquine may help treat COVID-19, but if mass prophylaxis is advised it's possible that demand will outweigh the supply of antimalarials, say Italian doctors in a letter published online today in the Annals of the Rheumatic Diseases. The results of prelimin
- Wontech Scores FDA Nod for Sandro Dual Laserhttps://practicaldermatology.com/news/wontech-scores-fda-nod-for-sandro-dual-laser/2460333/The U.S. Food and Drug Administration granted 510 (K) marketing clearance to Wontech’s Sandro Dual, a hybrid Nd:YAG & Alexandrite laser device. In the hybrid mode, by irradiating a short time difference between two wavelengths of 755nm and 1064nm, the laser accurately hits its
- BiomX’s BX001 for Acne-Prone Skin Performs Well in Phase 1 Trialhttps://practicaldermatology.com/news/biomxs-bx001-for-acne-prone-skin-performs-well-in-phase-1-1/2460328/BiomX Inc.’s lead candidate BX001 for acne-prone skin met its primary endpoint of safety and tolerability for both doses of BX001 as well as a statistically significant reduction of Cutibacterium acnes (C. acnes) levels for the high dos
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c
- Industry Responds to COVID-19: Allergan Foundation; AG Hair; Revancehttps://practicaldermatology.com/news/industry-responds-to-covid-19-allergan-foundation-ag-hair-revance/2460326/Allergan. Of the approximately $13 million in charitable grants the Allergan Foundation has awarded in 2020, a total of $2 million will be dedicated to more than 70 organizations responding to the local impact of the COVID-19 pandemic. Other grant recipients i
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- Castle Creek Biosciences Scores $75M Investmenthttps://practicaldermatology.com/news/castle-creek-biosciences-scores-75m-investment-1/2460319/Castle Creek Biosciences, Inc. received $75 million to support the advancement of multiple gene therapy candidates for rare diseases. The company plans to use the funding to advance and expand its gene therapy pipeline, led by the Phase 3 clinical development of FCX-007
- Pfizer's Abrocitinib Improves Atopic Dermatitis in Phase 3 Studyhttps://practicaldermatology.com/news/pfizers-abrocitinib-improves-atopic-dermatitis-in-phase-3-study/2460316/Top-line Results from a third Phase 3 trial of Pfizer's abrocitinib for moderate to severe atopic dermatitis showed improvements in skin
- CMS Updates Quality Reporting Requirements in Light of COVID-19https://practicaldermatology.com/news/cms-updates-quality-reporting-requirements/2460315/CMS is granting exceptions from reporting requirements and extensions for clinicians and providers participating in Medicare quality reporting programs with respect to upcoming measure reporting and data submission for those programs. For those programs with data submission deadl